All In Biotech

Drug Trial Radar · NCT02544529

Echothiophate Iodide for the Prevention of Progression of Myopia

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 1, 2016

Primary completion

Jun 1, 2016

Study completion Jun 1, 2016

Sponsor

Lead sponsor
Danbury Eye Physicians & Surgeons, PCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.

Conditions

  • Myopia

Interventions

  • Echothiophate Iodide 0.03% Ophthalmic SolutionDrug

    one drop to each eye three times per week for 18 weeks

  • Carboxymethylcellulose Sodium (0.5%)Drug

    one drop to each eye three times per week for 18 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cycloplegic RefractionTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Danbury Eye Physicians & Surgeons, PC

    Danbury, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.